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ABSTRACT 
Zika virus (ZIKV) is a member of the virus family flaviviridae and is transmitted via Aedes 
aegypti and Aedes albopictus mosquitos. These mosquitoes are the main vectors for the spread of 
Zika, dengue, chikungunya, West Nile virus, and other viruses. Monoclonal antibodies against 
dengue virus have been found to cross-react with Zika virus but show no ability to neutralize it. 
Furthermore, in vivo data has shown that Stat2-/- mice given pooled immune plasma from dengue 
positive donors exhibit a heightened disease phenotype when challenged with Zika virus. It is 
theorized that this increased severity of disease is due to antibody dependent enhancement (ADE). 
The goals of this study were to: (1) design a plasmid which, when encoded, creates an antigen that 
will be used to stimulate exclusively CD8+ T cells, and (2) generate an anti-ZIKV T cell repertoire 
in BALB/C mice. The gene sequence of NS3 was rearranged and fused with the open reading 
frame of ubiquitin for the innate targeting of the resultant protein to the proteasome. Peptide 
fragments would further be presented to CD8+ T cells in the context of MHC Class I molecules. 
Confirmation of transcription and translation of the vaccine plasmid was attempted by qRT-PCR 
and western blot, respectively. Plasmid was subsequently packaged into virus-like particles and 
injected into mice. Generation of Zika-specific CD8+ T cells was observed by use of MHC 
dextramer and 7-AAD/CFSE assay. Further investigation into the biological significance of the 
Zika-specific CD8+ T cell upregulation will help increase our understanding in the design and 
delivery of DNA vaccines.  
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CHAPTER ONE 
INTRODUCTION 
Zika Virus 
Zika virus (ZIKV) is a member of the virus family flaviviridae and is transmitted via Aedes 
aegypti and Aedes albopictus mosquitos[1]. The former species has gained attention in the past 
several years as the culprit of many country-wide ZIKV outbreaks. These mosquitoes are the main 
vectors for the spread of Zika, dengue, chikungunya, West Nile virus, and other viruses. ZIKV 
was first identified in Uganda in 1947 in monkeys, and was later identified in humans in 1952 [2]. 
The first large outbreak was reported on the Island of Yap in 2007 [3, 4]. Since then, outbreaks 
have occurred in French Polynesia, Puerto Rico, and Brazil. In February of 2016, the WHO 
declared ZIKV a Public Health Emergency of International Concern. Although ZIKV is estimated 
to show symptoms in less than 20% of people infected, this number rises to 65.6% of patients in 
pregnant women [5, 6].  ZIKV gained fame after it was linked to severe birth defects in Brazil such 
as microcephaly as well as congenital Zika syndrome – yielding complications including but not 
limited to: scarring to the back of the eye, decrease in overall brain tissue, seizures, and joints with 
limited range of motion [7]. 
Besides mosquito bites, ZIKV can be transmitted other ways. ZIKV can be transmitted 
sexually from either males or females to their partner [8]. In fact, one study tracked a case of male-
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to-female sexual transmission of ZIKV, and found that the virus persisted in the male 
partner’s semen for 80 days [9]. This is particularly concerning for people outside of the regions 
where A. Aegypti or A. Albopictus are present, as this may prove to be a much subtler method of 
infection. More notably, ZIKV has been known to be transmitted from mother to fetus by crossing 
the placenta. It is believed that the anti-ZIKV antibody may play a role in transplacental transport 
of the virus [10]. Amongst the different immunoglobulin classes, only IgG can cross the placenta. 
Once inside, IgG then binds to the neonatal Fc receptor on the placenta. The Fc receptor is 
responsible for the transport of many essential antibodies of the IgG class from mother to fetus 
[11, 12]. While the transfer of neutralizing Immunoglobulin from mother to fetus is normally 
beneficial, passage of pathogenic antibody complexes can induce disease in newborns [13]. In the 
context of ZIKV, when a mother can pass neutralizing anti-ZIKV IgG transplacentally, it can 
protect the fetus from ZIKV infection. On the contrary, if the mother passes non-neutralizing 
ZIKV-IgG immune complexes to the fetus, these complexes can be captured by the neonatal Fc 
receptor on the placenta and transferred to the fetus where the virus may replicate [10]. After 
infection, it has been shown in mouse models that the fetal demise most noted with ZIKV infection 
is associated with type I IFN response. It was found that the activation of the type I IFN response 
in the Ifnar1+/- fetuses lead to fetal hypoxia and resorption [14].  
Dengue Virus and ADE 
As stated earlier, the mosquitoes that carry Zika are also vectors for the spread of both 
dengue virus (DENV) and West Nile virus (WNV) [15]. Dengue virus has four serotypes that 
differ by 30-35%, with their envelope protein sequences differing from the ZIKV envelope protein 
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sequence by 41-46% [16] – indicating significant homology. Dengue infection can be 
asymptomatic, or present in two forms of illness – dengue fever and dengue hemorrhagic fever 
(DHF). DHF is characterized by plasma leakage, hemorrhaging, and thrombocytopenia (low blood 
platelet count) [17, 18]. Primary infection by DENV leads to life-long immunity to only the 
infecting serotype, but not the remaining three [19-21]. Secondary exposure to the remaining three 
serotypes is often associated with the development of dengue hemorrhagic fever [19, 22]. To shed 
light on why this occurs, when someone is infected with any serotype of DENV (i.e. DENV1), 
they develop antibodies specific to that infecting serotype. This infection is characterized by flu-
like symptoms, fever, and general symptoms of malaise for approximately one week. The patient 
then recovers from the disease and develops a life-long immunity to that infecting serotype [19-
21]. When a patient is infected with a second serotype of DENV (i.e. DENV 2-4), it is believed 
that the pre-existing heterologous dengue antibodies made from the first exposure to the virus 
recognizes the new, infecting virus and forms an antigen-antibody complex. This complex then 
binds to and is internalized by immunoglobulin Fc receptors on the cell membrane of macrophages 
[23-26]. Because the antibody is heterologous and therefore less specific to the invading virus, the 
virus is not completely neutralized inside the macrophages but is instead free to replicate once 
inside. This process is known as antibody-dependent enhancement (ADE) and is thought to aid 
viruses in infecting monocytes more efficiently [23, 27].  
Many efforts have gone into characterizing the process by which secondary DENV 
infection escapes neutralization within macrophages [28-32]. Some studies suggest that DENV is 
responsible for a reduced IFNβ response, which would result in the decreased killing of virus 
intracellularly [28]. This occurs as DENV upregulates IL-10 production. High levels of IL-10 in 
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turn activate expression of SOCS3 to inactivate the JAK/STAT pathway [30] necessary to induce 
interferon response.  
ZIKV-DENV Cross-reactivity 
Importantly, it has been shown that human monoclonal antibodies generated from DENV-
infected patients cross-react with ZIKV but show no ability to neutralize the virus [33]. In a study 
conducted by the Dejnirattisai group, plasma was collected from children in northeast Thailand 
following secondary infection with DENV serotypes 1-4. Plasma was assessed for binding to 
ZIKV by capture ELISA as well as neutralization of ZIKV. In all cases, DENV-immune plasma 
bound to both DENV and the HD78788 (Africa) or PF13 (French Polynesia) strains of ZIKV very 
similarly. In addition, when tested for virus-neutralization ability, all the plasma from the patients 
were able to neutralize DENV at nearly 100% at the lowest antibody dilution used (1:50). 
Neutralization of ZIKV, however, was considerably lower. Most plasma samples showed no 
appreciable neutralization of either HD78788 or PF13 strains of ZIKV at 1:50 dilution. Lastly, in 
a well-known study, the Screaton group assessed the ability of plasma from DENV-infected 
subjects to promote ADE in the human myeloid cell line U937. This cell line is normally resistant 
to infection by DENV only in the absence of ADE [34]. It was found that U937 cells were also 
poorly permissive to ZIKV, with infection of cells being <0.6% in the absence of ADE. To induce 
an ADE response, ZIKV was pre-incubated with a titration of pooled serum collected from 
convalescent subjects at 1-2 weeks after recovery from infection with DENV and was then used 
to infect new U937 cells. Pooled serum from convalescent subjects led to >100-fold enhancement 
of infection of cells by ZIKV, whereas plasma pooled from DENV-free patients did not enhance 
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infection. In fact, this study found that in all but one case, plasma taken from DENV-infected 
subjects enhanced ZIKV infection [33].  
While these claims seem well-backed in vitro, in vivo evidence proved more convincing. 
Stat2-/- C57BL/6 mice were used as they display significant morbidity and mortality in response 
to ZIKV infection [35]. In a study by the Lim group, Stat2-/- mice were given pooled immune 
plasma from control, DENV, or WNV positive donors. Two hours post-transfer, all mice were 
infected with ZIKV and monitored daily for survival, weight loss, and other symptoms. Mice that 
received control plasma exhibited a 93.3% survival rate 14 days post infection, whereas mice that 
received DENV positive plasma succumbed to infection by day 8 [36]. Mice that received WNV 
immune plasma had a slight decrease in survival rate, but the difference was not statistically 
significant. This difference in survival rate can possibly attributed to the drastic difference in 
sequence homology in WNV compared to ZIKV than with DENV.  
Although we see obvious instance of ADE in vitro as well as in vivo, we have yet to see 
any cases of ZIKV-induced ADE in humans. There are three main theories as to why: first, 
antibodies derived from serotype-specific infections of DENV might affect ZIKV infection 
differently. For example, infections in the sequence of DENV-3 followed by DENV-2 result in 
more severe clinical outcome than do any of the other secondary infection sequences [37]. 
Clinically, this may mean that, in order to become predisposed to ZIKV-induced ADE, a patient 
may need to be infected in a specific temporal and strain-specific order of DENV/ZIKV. Secondly, 
the interval between DENV followed by ZIKV infection may regulate disease severity. If an 
individual becomes infected with initial as well as secondary DENV within two years of each 
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other, the severity of disease remains low. If an individual becomes infected with two strains of 
DENV between 2-20 years of each infection, they are likely to develop DHF and DHF-related 
symptoms [38, 39]. Lastly, due to the dependence on time for severity of secondary infection, it 
may be possible that ZIKV-induced ADE has occurred in countries that do not report these cases. 
Further epidemiological studies in countries where ZIKV has persisted for over 70 years are 
needed.  
ZIKV Vaccines and Protein Targeting Strategies 
Many great efforts have been made to create a vaccine for ZIKV. These vaccine candidates 
range from administration of live-attenuated virus to mRNA and DNA intradermal injections [40-
42]. In these studies, prM and E proteins were targeted as they are located on the exterior of the 
viral particle – albeit with considerably differing amino acid sequences across strains. On the 
contrary, a predictive epitope analysis found that all CD8+ T-cell epitopes on the NS3 amino acid 
sequence were conserved across 54 different ZIKV genomes [43]. Normally, the NS3 protein is 
covalently bonded to NS2B, an anchor protein which functions as a cofactor and promotes the 
productive folding and activity of NS3 [44]. The N-terminal region of NS3 protein encodes a serine 
protease, while the latter region encodes for helicase. This NS2B-NS3pro complex is responsible 
for the cleavage of the ZIKV polyprotein precursor and generation of the other proteins in the 
ZIKV viral genome [44]. As this protein is essential for the functionality of every other viral 
protein, as well as the fact that its CD8+ T-cell epitopes are conserved across 54 different ZIKV 
genomes, makes it an attractive target for vaccine strategies.  
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DNA Vaccines 
One vaccination method that has recently gamed popularity in its ability to induce a CD8+ 
T cell response is the DNA vaccine. Whereas most current vaccines are composed of either killed 
pathogens, pathogen subunits, or live-attenuated viruses, DNA vaccines are composed of just that 
– a DNA plasmid with a possible adjuvant [45]. DNA vaccines involve the immunization of a 
circular DNA plasmid that contains the gene(s) of interest that encode for an antigen [46]. This 
plasmid is then taken up by local cells and is transcribed/translated into an immunizing protein.  
Once the plasmid has entered a localized cell, there are two theories as to how the immune 
system is activated. In the first theory, the antigen presenting cells that are mobilized to the site of 
injection are transfected by plasmid DNA. These APCs can present the antigen within the context 
of an MHC Class I and II molecules depending on the circumstance. In the second theory, plasmid 
DNA is internalized and expressed by any nearby somatic cell. The plasmid is then 
transcribed/translated - generating the protein of interest. Antigen-presenting cells then 
phagocytose plasmid-transfected somatic cells and present antigen to both CD4/8+ cells [47].  
DNA vaccines have become attractive vaccine candidates due to their stability and ease of 
delivery [48]. Not only does injection of naked DNA stimulate effective and long-term immune 
responses, but it also allows for the engineering of artificial immunogens and co-expression of 
immunogenic proteins that may induce an enhanced response over antigens expressed in nature 
[49]. In addition, compared to the short life of injected protein vaccines, DNA vaccines can provide 
tissue expression of antigens over a much longer period of time, thus gaining the ability to 
constantly stimulate CD4+ and CD8+ cells [47]. Furthermore, DNA vaccines have been found to 
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be very safe for subjects receiving them. Initially, it was thought that these plasmids would 
spontaneously integrate into chromosomes and induce the activation of oncogenes – in a method 
similar to that of HPV [47]. Subsequent studies confirmed that DNA vaccines have an extremely 
low probability of integrating into the human genome [50].  
Specific Induction of Cell-mediated Immune Response 
A study by the Rodriguez group has provided insight into the design of a DNA vaccine to 
sharply induce a CD8+ response while inhibiting antibody upregulation. In 1997, the Rodriguez 
group used a novel approach in order to induce CD8+ response to a lymphocytic choriomeningitis 
virus (LCMV) nucleoprotein (NP). To do so, the group fused the open reading frame (ORF) of 
ubiquitin to the ORF of their protein of interest by PCR. In an in vitro model, the resulting 
degradation of the protein was so efficient that the protein product was hardly detectable except in 
the presence of proteasome inhibitor [51]. BALB/C and C57BL/6 mice were immunized with the 
plasmid three times intramuscularly and CTL/anti-LCMV-NP antibody levels were monitored. It 
was found that wild type LCMV as well as a plasmid encoding for a non-ubiquitinated version of 
NP antigen robustly induced an antibody response. Furthermore, in mice that were injected with a 
plasmid encoding for a ubiquitinated NP antigen, there was no detectable anti-LCMV-NP antibody 
induction. The result was the same for both strains of mouse. Furthermore, it was also found that 
mice vaccinated with the ubiquitinated NP plasmid (U-NP) exhibited improved CTL induction, as 
evidenced by an increase in percent specific chromium-51 release [51]. After immunization, half 
the mice in each group were infected with LCMV. Unsurprisingly, it was found that mice not 
immunized with U-NP displayed minimal CTL activity 4 days post injection (dpi). In contrast, the 
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animals that were effectively immunized displayed readily detectable levels of anti-LCMV CTLs 
at 4 dpi. The mice that received nonubiquitinated NP antigen did mount LCMV-specific immune 
responses, but CTL levels were lower and not found to be significant. Lastly, immunity of the mice 
to a lethal dose of LCMV was tested. Mice were immunized as normal, challenged with 20 LD50 
LCMV, and LCMV titers in the spleens were determined. In mice previously immunized with a 
sub-lethal dose of LCMV, no LCMV virus titer was detected after administration with lethal 
LCMV (neg. control). Mice immunized with nonubiquitinated NP antigen showed significant 
reduction in virus titer (2-3 fold), however virus was still detectable in all eight mice. Contrary to 
this result, mice immunized with U-NP had no detectable virus in their splenic tissue. Naïve mice 
succumbed 6 to 8 dpi, whereas six mice treated with nonubiquitinated NP plasmid survived, and 
all mice treated with U-NP survived. This study was the first to show that covalent attachment of 
ubiquitin to NP enhances degradation and antigen presentation, abolishes antibody production in 
vivo, and enhances CTL induction and antiviral ability in vivo.  
DNA Vaccine Immunogenicity and Delivery 
Over the years, there have been many attempts to enhance the immunogenicity of DNA 
vaccines. It has been found that intrinsic elements of plasmid DNA can enhance immunogenicity. 
The innate immune system uses pattern recognition receptors (PRRs) in order to sense pathogens 
and induce appropriate immune responses [52]. In humans, toll-like receptor-9 (TLR9) is a 
cytosolic PRR that binds to DNA sequences containing unmethylated cytosine-guanine (CpG) 
motifs [53, 54]. In the human genome, unmethylated CpG motifs are rare, whereas in bacterial 
genomes the observance of unmethylated CpG motifs is a common occurrence. Therefore, 
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inclusion of a CpG motif in a DNA vaccine vector acts to activate TLR9 and subsequently MyD88 
to induce an innate immune response [55, 56]. In addition to the inclusion of other nucleotide bases 
within the vaccine backbone, adjuvants can be delivered alongside the non-immunogenic plasmid 
in order to increase its immunogenicity. It has been found that specific cytokines can be delivered 
with DNA plasmids [57]. For example, IL-12 administered with HIV DNA plasmids has been 
shown to enhance TH1 immunity, and to decrease the Th2 response [58]. In addition, cationic 
liposomes can be used to increase the immunogenicity of a plasmid. Cationic liposomes take up 
plasmid DNA and facilitate their entry into the cytoplasm by penetrating the lipid bilayer of the 
cellular membrane [59] They are formed by a combination of electrostatic attraction as well as 
hydrophobic interaction and have been used as non-viral vectors for the intracellular delivery of 
genes [60]. In 1992, it was found that the major capsid protein L1 of HPV-16 can be expressed in 
a eukaryotic expression system [61]. The L1 protein has been shown to self-assemble into virus-
like particles (VLPs) that are highly immunogenic [62]. In fact, it has been shown that HPV-16 
VLPs alone can induce cell-mediated immunity against HPV-16 in mice [63]. Furthermore, VLPs 
can be disassembled by means of a reducing agent, and reassembled by means of CaCl2 [64]. 
Exposure of disassembled VLPs to purified DNA along with increasing concentrations of CaCl2 
allows the VLPs to re-form around the plasmid, creating what is known as a pseudovirus (PV). 
PVs can be used orally as well as systemically to induce host immunity against the protein that the 
plasmid-bearing PV expresses. It has been found that PV immunization induces a stronger CTL 
response than a naked DNA plasmid encoding the same epitope [65]. Virus-like particles present 
an all-in-one delivery + adjuvant system, allowing for maximal simplicity in designing and 
applying a DNA vaccine.  
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CHAPTER TWO 
MATERIALS AND METHODS 
Rearranged Ub/NS3 Gene Design 
The PRVABC59/2015 strain of ZIKV in Homo Sapiens was used to obtain the NS3 gene 
sequence (Accession Number: KX87101.3). The NS3 gene region was then split into three parts. 
In constructing this sequence, the last 30 bases of segment two were placed at the beginning of the 
rearranged gene sequence, with region 3 following shortly after. The last 30 nucleotides of region 
one were then placed next, with region two following, and so on (Fig. 1). With this method, any 
epitope that may have been disrupted due to the rearrangement of the gene region would then be 
recreated by re-addition of the disrupted DNA sequences to the beginning of each segment. The 
sequence encoding for both a human/mouse ubiquitin monomer was obtained (Accession Number: 
P0CG50). The glycine residue at 76 was modified to an alanine residue, and this sequence was 
then placed in front of the rearranged NS3 sequence. Before this combined Ub/NS3 sequence, a 
Kozak sequence was placed in order to ensure efficient transcription of the plasmid. Upstream the 
Kozak sequence, linker DNA as well as an EcoRI restriction site was placed to facilitate proper 
cloning of the gene segment into the vector of interest. Downstream the re-arranged Ub/NS3 gene 
sequence, a stop codon was placed along with linker DNA and a NotI restriction site. This 
nucleotide sequence was ordered through ThermoFisher’s GeneArt program.  
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Figure 1. Detailed Schematic of Plasmid Design. The gene sequence encoding for the NS3 
protein was split into three groups (denoted 1, 2, 3). The 30 nucleotide bases before and after any 
cleaved sequence were placed in front of each region to preserve any epitopes that may have been 
disrupted. The ORF gene encoding for a mouse monomer of ubiquitin was placed immediately 
upstream the rearranged NS3 sequence. A glycine at the 76 residue was modified to encode an 
alanine to enhance the stability of the Ub/NS3 complex.  
 
Generation of Chemically-Competent DH5α E. Coli 
A single colony of DH5α E. Coli was taken from an LB plate and inoculated into 4mL of 
LB medium (Sigma) shaking at 225 rpm overnight at 37oC. The overnight culture was then used 
to inoculate 200mL of LB media until the A600 reached 0.4-0.6 (cells were harvested once an A600 
of any value past 0.4 was obtained). Cells were pelleted by centrifugation at 7120rpm for 15 
minutes at 4oC. Supernatant was discarded, and pelleted cells were resuspended in buffer 
containing Rubidium Chloride, Manganese Chloride, Potassium Acetate, Calcium Chloride, and 
Glycerol and incubated on ice for 5 minutes. Cells were centrifuged at the same conditions, and 
NS3
Gene 
fragments
New  construct
1                   2                   3
3                2                1     
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the pellet was resuspended in buffer containing MOPS, Rubidium Chloride, Calcium Chloride, 
and Glycerol. Cells were quick frozen with dry ice and ethanol, and stored at -80oC until use.  
Plasmid Ligation 
The NS3 gene was delivered in a proprietary ThermoFisher vector in a lyophilized form. 
Plasmid DNA was resuspended in Molecular Biology Grade water (ThermoFisher) to a 
concentration of approximately 200ng/uL. DNA was digested with FastDigest (FD) EcoRI and 
NotI for 15 minutes in a 37oC heat block. The digested DNA was then loaded directly onto a 1% 
Agarose gel and allowed to run for 40 minutes at 80V. The 2.2kb Ub/NS3 DNA was exposed to 
440nm UV light in the imaging room and excised. The gel slice was placed into a clear, 1.5mL 
microcentrifuge tube and the purified DNA was extracted using a QIAquick Gel Extraction Kit 
(Qiagen). This gene fragment was stored in a -20oC freezer as the pVAX1 vector (ThermoFisher) 
was digested with FD EcoRI and FDNotI, run on a gel, and extracted using the same kit. The 
Ub/NS3 gene fragment was ligated using a 3:1 ratio of insert DNA (Ub/NS3) to vector DNA 
(pVAX1) at room temperature for 10 using T4 DNA ligase.  
Bacterial Transformation 
 Previously made chemically competent DH5α E. coli were removed from -80oC freezer 
and thawed on ice for 25 minutes. Ligated Ub/NS3/pVAX1 were introduced to the E. coli and 
remained on ice for 30 more minutes. Heat shock transformation occurred by placing the tube into 
a 42oC heat block for 45 seconds and back on ice for 2 minutes. 1mL SOC media was added to the 
E. coli and was grown in a shaking incubator at 37oC for 45 minutes. The E. coli was then spun 
down at 9000 rpm for 2 minutes, resuspended in 200μL SOC media, and streaked on an LB + 
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kanamycin plate. Once dry, the plate was inverted and incubated overnight at 37oC. Colonies from 
the plate were inoculated into 2mL LB + Kan media, and a Miniprep was conducted using a 
QIAprep Spin Miniprep Kit according to the manufacturer’s instructions (Qiagen). Plasmid was 
subsequently re-digested with FD EcoRI and NotI. Upon observance of correct band digestion, 
plasmid was sent out for sequencing (ACGT, Inc) for confirmation of correct insertion.  
Plasmid Transfection 
293T cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) with 10% Fetal Bovine 
Serum (FBS) and 1% Penicillin/Streptomycin. Cells were split upon reaching 90% confluence 
(every 2-3 days). Upon sufficient generation of 293T cells, 10μg of Ub/NS3/pVAX1 plasmid were 
transfected using 1 mg/mL polyethylenimine (PEI) overnight. Media was removed the next 
morning and cells were cultured in DMEM. For subsequent experiments using proteasome 
inhibitor, 50μM MG132 was added to cell culture medium overnight at either 12, 36, or 60 hours 
after transfection.  
qRT-PCR 
After 293T cells were transfected as described above, purification of total RNA was conducted 
using an RNeasy mini Kit according to the manufacturer’s instructions (Qiagen). First-Strand 
cDNA was then synthesized using a GoScript Reverse Transcription System according to the 
manufacturer’s instructions (Promega). In a PCR tube, the RNA harvested from transfected 293T 
cells was incubated with NS3 specific primers along with GAPDH primers in a heat block at 70oC 
for 5 minutes. Tubes were immediately placed on ice for 10 minutes. RNA/primer mix was mixed 
with GoScript Reverse Transcription mix in a 3:1 ratio for each reaction. Tubes were placed on a 
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heat block at 25oC for 5 minutes, then placed on a heat block at 42oC for one hour. Reverse 
transcriptase was inactivated by placing tubes in a heat block at 70oC for 15 minutes. Quantitative 
Reverse Transcriptase PCR (qRT-PCR) was conducted using iTaq Universal SYBR Green 
Supermix (Bio-Rad) using NS3 specific primers as well as GAPDH specific primers. Fold 
induction was measured as 2-ΔΔCT.  
Western Blot 
293T cells were cultured, transfected, and treated with proteasome inhibitor as described above. 
After treatment with MG132, 293T cells were treated with 0.25% trypsin for 5 minutes at 37oC in 
5% CO2. 293T cells were resuspended in DMEM, centrifuged at 1200 rpm for 5 minutes, and cell 
pellets were resuspended in RIPA buffer (10mM Tris-Cl pH 8.0, 1mM EDTA, 0.5mM EGTA, % 
Triton X-100, 0.1% Sodium Deoxycholate, 0.1% SDS, 140mM NaCl, 1mM PMSF) with freshly 
added Halt proteinase inhibitor. Total protein concentration was calculated via Bradford Assay 
(Bio-Rad) and 6x SDS Loading Buffer (.5M Tris-Cl pH 6.8, glycerol, beta-mercaptoethanol, SDS, 
1% bromophenol blue) was added to 20μg of total protein. Protein was denatured at 100oC for 10 
minutes and then placed on ice for 2-3 minutes. Proteins were run on a 12% polyacrylamide gel 
for 20 minutes at 80V and for 40 minutes at 120V, or until the dye line reached the bottom of the 
gel. Bands from the polyacrylamide gel were transferred to a nitrocellulose membrane using an 
iBlot Gel Transfer Device (ThermoFisher). Membrane was blocked in 5% blocking buffer (5% 
Non-Fat Milk in PBS) for 1 hour. Membrane was washed in PBS-T and blocked in 5% Blocking 
Buffer containing a 1:1000 dilution of anti-ZIKV NS3 antibody (Genetex) overnight. The next 
day, the membrane was washed with PBS-T for 20 minutes, and the membrane was blocked in 5% 
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Blocking Buffer with a 1:2000 dilution of secondary HRP conjugated Goat anti-rabbit antibody 
for 1 hour. Membrane was washed in PBS-T for 20 minutes, and then exposed to 10mL 
Chemiluminescent substrate (Thermo) for 3 minutes devoid of light. Proteins were visualized 
using a FluorChem E system (ProteinSimple) with 30 second exposure time. Overexposed gels 
were visualized using a 120 second exposure time.   
VLP construction 
L1-expressing bacterial-plasmid as well as recombinant L1 baculovirus were created prior to my 
arrival using a pFast Bac system. Insect cells were grown at 2 x 106 cells/mL and allowed to settle 
to the bottom of a T-182 flask. After aspiration, 4mL of baculovirus stock was added to the flask 
and was placed in a 27oC incubator for 15 minutes. Flask was rocked back and forth for 2 minutes 
at a time in between 15-minute incubation intervals three times.  25mL of ESF921 media was 
added to the flask and allowed to incubate for 3-4 days at 27oC. After 7-10 days, cells and 
supernatant were collected and centrifuged at 1200 rpm for 5 minutes. Supernatant was collected 
to further infect cells. After sufficient baculovirus production, Sf9 cells were added to a suspension 
flask in 300mL ESF921 media and were allowed to grow for 1 week. Cells were added in a 1:1 
ratio to baculovirus, and were placed on a rocker shaker for 1 hour at room temperature (devoid of 
light). 4 mL of virus-sf9 cell mixture were placed onto 150x25mm petri dishes along with 21mL 
ESF921 media. After 3-4 days, infected cells were spun at 4000rpm for 15 minutes. Pellets which 
contained VLPs were stored in a -20oC freezer. VLPs were further purified using size exclusion 
chromatography and confirmed by western blot.  
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Insertion of DNA Plasmid into VLP 
 BPV L1-VLPs were mixed with a disruption buffer containing EGTA and DTT in a 1:1 
ratio and incubated for 60 minutes at room temperature. Plasmids are then added in a 1:10 ratio at 
835.2ng/μL. A stop buffer containing CaCl2 is added dropwise in a 1:1 ratio in 20% of the total 
volume increments. After each addition, the VLPs are mixed and incubated for 10 minutes at room 
temperature. 20% more stop buffer is added every ten minutes. The mixture is incubated at room 
temperature for 4 hours and then overnight at 4oC. Reassembly of VLPs is examined via electron 
microscopy.  
Vaccine Administration and Splenocyte Harvesting 
 For experiments with VLPs, 1x1010 PV were diluted into 50μL PBS to a final dose of 2 
x108 PV. PV were injected intramuscularly into the rear right quadricep of BALB/C Mice. For 
experiments with Gardiquimod Vaccigrade (Invivogen), 18ug/mouse and 25ug/mouse 
Gardiquimod were supplemented with plasmid in female and male mice, respectively. The mice 
were given different amounts of adjuvant based on average weight. Mice were boosted after 3 
weeks, and spleens were harvested after 1 week. Mice were euthanized via CO2 asphyxiation 
followed by cervical dislocation and spleens were removed. Splenocytes were harvested by 
passing mouse spleen through a 70μm filter using the blunt end of a syringe. RPMI-1640 was 
passed over the filter to collect the splenoctyes. Splenocytes were then centrifuged at 1200 rpm for 
5 minutes. After aspirating the supernatant, cells were resuspended in 2mLs Ack lysis buffer to 
remove any erythrocytes present. After the cell culture solution turned a soft pink, or after 5 
minutes maximum had passed, 20mL RPMI-1640 were added and cells were pelleted once again. 
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Splenocyte Stimulation and CFSE Assay 
Splenocytes were seeded at 1*106 cells/mL into 100μL wells in a 96-well plate, 2 plates 
per mouse. Media containing 10% T-stim (IL-2 culture supplement, Corning) and 10μg/mL 
peptide (GYISTRVEM, Genscript) was prepared and added to each well.  Splenocytes were 
stimulated for 7 days. Briefly, P815 cells were loaded with peptide at 5mg/mL for 2 hours at 37oC 
followed by labeling of CFSE fluorescent dye in RPMI 1640 medium without FBS for 10 minutes. 
Splenocytes were then incubated with the P815 cells at 1:1, 1:3, 1:10 target to effector cell ratios 
for 4 hours at 37oC. Cells were then spun down and stained with 7-AAD for 15 minutes The 
cultures were than analyzed via flow cytometry for assessment of the percentage of 7-
AAD/CFSE+/+ labeled P815 cells.  
Flow Cytometry 
Splenocytes were counted and 2 x 106 cells were added to each tube. Samples were washed 
in FACS Buffer (1% FBS in PBS) and centrifuged at 1500rpm for 15 minutes at 4oC. Samples 
were then blocked with Fc block on ice in order to block for non-specific antibody binding and 
washed again. Samples were stained with Anti-NS3 Dextramer-PE (Immudex), followed by Anti-
CD8a-FITC antibody for MHC dextramer experiments or with 7-AAD and CFSE in cytotoxicity 
experiments. Tubes were washed and imaged by flow cytometry.  
Statistical Analysis 
All statistical analyses were conducted using GraphPad software (Prism). All data shown was 
analyzed using a two-way ANOVA or Student’s T test and depicts the standard error of the mean 
unless otherwise specified
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              CHAPTER THREE 
ASSEMBLY AND CHARACTERIZATION OF THE REARRANGED UB/NS3 GENE 
Introduction 
DENV infection can be asymptomatic, or present itself as dengue hemorrhagic fever 
(DHF). Primary infection of DENV leads to life-long immunity to the infecting serotype, but not 
the remaining three [19-21]. Secondary exposure to the remaining three serotypes is often 
associated with the development of DHF. DHF is characterized by plasma leakage, hemorrhaging, 
and thrombocytopenia [17, 18]. It is believed that the antibodies created during initial infection are 
elicited during secondary infection. These antibodies are specific enough to the different antigenic 
strain to sequester the virus and opsonize it onto Fc-receptor bearing cells, but not specific enough 
to completely neutralize the virus once inside. This process is known as antibody-dediated 
enhancement (ADE) and is thought to be the mechanism by which DHF occurs. As alluded to 
earlier, ZIKV and DENV share significant sequence homology. Dengue virus has four serotypes 
that differ by 30-35%, with their envelope protein sequences differing from the ZIKV envelope 
protein sequence by 41-46% [66].  In addition, it has been found that human monoclonal antibodies 
generated from DENV-infected patients cross-react with ZIKV but show no ability to neutralize 
the virus [33]. As monoclonal antibodies generated from DENV infection have been shown to bind 
to and cause ADE due to ZIKV infection, a vaccine effort aimed at generating ZIKV-specific 
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antibodies can be obviously problematic. Therefore, a ZIKV prevention effort should be 
aimed at generating a CD8+ T-cell response in order to confer immunity to ZIKV infectionA 
simple yet effective method to safely induce the upregulation of antigen-specific CD8+ T cells is 
the use of DNA vaccines. Unlike killed-, subunit-, or live-attenuated virus vaccines, DNA vaccines 
are based on bacterial plasmids that encode for antigens [67]. However, unlike conventional 
vaccines, DNA vaccines must gain entry into the nucleus of the cell in order to induce transcription 
and translation of the antigen and eventual MHC presentation. The first proof-of-concept DNA 
vaccine was conducted in 1990 and involved injecting DNA vectors expressing luciferase and 
beta-galactosidase. The expression of these reporter genes in vivo was easily detectable and lasted 
two months [68]. Since then, adjustments have been made on the methods regarding design and 
delivery of plasmid into in vivo carriers [69].  
It has been previously shown that ubiquitination of a viral protein enhances CTL induction 
as well as antiviral protection while completely abrogating antibody induction [70]. The objective 
of this method is to create a plasmid which encodes for a ubiquitin-tagged protein that is 
immediately directed to the proteasome for destruction. The resultant short peptides will then be 
transported through the ER membrane by the TAP transporter. The peptides will then be loaded 
onto the MHC class I molecule, where the molecule + peptide complex will be transported to the 
cell surface for further stimulation of CD8+ T cells [71-73]. With this finding, we utilized the 
design method of the Rodriguez paper [51], whilst taking advantage of current laboratory 
technologies. 
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Firstly, the gene sequence encoding for the NS3 protein was rearranged so that it will 
become unstable and non-functional, while retaining all of its potential CTL epitopes. The ORF 
of a gene encoding for a ubiquitin monomer was placed in front of the NS3 protein in direct 
succession in order to create a protein that innately expressed a K48 residue to be further 
polyubiquitinated (Fig. 1). This gene, once transcribed/translated, will be targeted for immediate 
destruction by the proteasome in order to eventually generate an anti-Ub/NS3 CD8+ T cell 
repertoire to confer immunity against ZIKV infection.  
Assembly of Vaccine Plasmid 
Confirmation of correct insertion of this rearranged gene sequence, as well as further 
testing of proper transcription/translation of the aforementioned gene sequence, is critical for the 
proper functionality of this plasmid as a vaccine candidate. Therefore, I began my project by 
inserting the rearranged Ub/NS3 sequence into the only FDA approved vector for the use in DNA 
vaccines in Humans – pVAX1. The Ub/NS3 sequence was designed to contain restriction sites 
that were not found in the delivery vector from ThermoFisher but were found only once in pVAX1. 
For this reason, EcoRI (G^AATTC) and NotI (GC^GGCCGC) restriction sites were inserted into 
the rearranged Ub/NS3 sequence. Successful ligation occurred at a ratio of 1:8, vector: insert (Fig. 
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2A). Successful transformation was further verified by DNA sequencing performed by ATCG, 
Inc. (Fig. 2B).  
Figure 2. Successful Ligation of Rearranged Ub/NS3 Insert into pVAX1 Vector. Ub/NS3 
insert was cloned into DH5α E. coli and subsequently purified via Qia Quickspin Mini Prep Kit 
(Qiagen). (A) Insert was excised using EcoRI and NotI restriction enzymes and inserted into 
pVAX1 vector at a ratio of 1:8, vector: insert via chemical transformation. DNA was run on a 1% 
agarose gel with ethidium bromide and was visualized by 440nm UV light. (B) After successful 
ligation, 10ng of DNA were sent to ATCG, Inc. for sequencing. 
 
Expression of Ub/NS3 Gene in Transfected 293T Cells 
In 1977, human embryonic kidney (HEK) cells were transformed with fragments of 
adenovirus type 5 DNA. The transformed cells (designated 293), exhibited many characteristics 
specific to the adenovirus genome and transcribed a large portion of it [74]. Since then, the 
biochemical machinery of HEK293 cells has been thoroughly studied, and has been shown to carry 
A B 
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out almost all post-translational processing needed to generate a functional, mature protein(s) from 
plasmid DNA [75]. Furthermore, HEK293 cells have been used to stably express transfected 
proteins over a long period of time. For this, we investigated the ability of the insert to successfully 
be taken up by the cells and express the mRNA of interest. 10μg of plasmid DNA was complexed 
with polyethylenimine and delivered to 293T cells dropwise. Cells were treated with complexed 
DNA overnight. RNA was isolated using an RNeasy RNA isolation kit (Qiagen). RNA reverse 
transcription was conducted using a GoScript Reverse Transcriptase System (Promega). qRT-PCR 
was conducted using primers specific to the Ub/NS3 sequence as well as primers specific to 
GAPDH (neg. control). 293T cells transfected with the Ub/NS3 sequence displayed a 150,562-
fold increase in expression compared to untransfected cells. Although this fold change is 
drastically high due to low expression in control cells, gene transcription was certainly confirmed 
(Fig. 3A). The PCR products were run on a 1% agarose gel in order to confirm the primers bound 
specifically to the Ub/NS3 cDNA sequence. As seen in Fig. 3B, primers bound to the transfected 
293T cells created a 512bp band. No primer binding occurred in untransfected cells – confirming 
the proper transcription of our gene of interest. To further corroborate these results, all GAPDH 
primers bound to both transfected and untransfected cells produced the same band size. These 
results confirm that the vaccine plasmid in question is indeed transcribed and is so at a very high 
expression rate.  
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Figure 3. Fold Change in Expression of Ub/NS3 Gene Sequence in 293T Cells. 293T cells were 
transfected with rearranged Ub/NS3 in PEI overnight. RNA was further isolated, cDNA was 
synthesized, and analysis of gene expression was conducted by qRT-PCR. (A) Relative gene 
expression of rearranged Ub/NS3 and GAPDH. (B) PCR products were run on a 1% agarose gel 
for 40 minutes at 80V. Band size was observed. Each treatment condition was replicated twice. 
Data was analyzed by student’s T test. Error bars depict standard error of the mean. ** indicates a 
p value <0.01 
Analysis of Proper Protein Expression 
Although we have evidence to prove that the gene of interest was transcribed successfully, 
this does not always ensure protein translation. In order for a gene to be successfully transfected 
and transcribed, it needs to encode for a nucleotide sequence that matches exactly what we have 
designed, contains no out-of-frame mutations, and most importantly, has a functional Kozak 
sequence.  One concern with regards to rearranging a gene sequence in order to encode for an 
altered protein is the unfolded protein response (UPR). The majority of proteins that a cell secretes 
A B 
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or displays on its surface enter first through the ER, where they fold, assemble, and can possibly 
be loaded onto MHC class I molecules [76]. Only properly assembled proteins can advance from 
the ER to the cell surface. In order to make sure that proteins are consistently folded correctly, a 
collection of intracellular transduction pathways, dubbed the “Unfolded Protein Response” is 
activated. The UPR includes phenomena such as global attenuation of mRNA transcription,  and 
activation of ER-associated degradation pathways to destroy misfolded proteins [77]. In the 
context of our project, activation of the UPR is not inherently detrimental. When the UPR is 
activated and improperly folded proteins are detected, they are delivered for proteasomal 
degradation. Since the creation of an antigen-specific T cell repertoire depends on direction of 
these proteins to the proteasome, the UPR may assist in this overall objective [78]. However, prior 
to transfection of 293T cells, multiple protein structural prediction modelling softwares were used 
to ensure significant homology to the current NS3 structure (Fig. 4).  
  
 
Naturally, there comes a problem with visualizing a protein that is innately ubiquitinated. 
It is widely known that many proteins are targeted for degradation by covalent ligation to ubiquitin 
Figure 4. Predicted Secondary Structure of Ub/NS3 Protein. Swiss-model protein 
visualization software was used to predict secondary structure of the re-arranged Ub/NS3 
protein.   
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[79]. Therefore, any protein that is innately ubiquitinated is targeted for immediate destruction. To 
address this issue, one can utilize a proteasome inhibitor. 293T cells were once again transfected 
with rearranged Ub/NS3/pVAX1 overnight. In the morning, media was changed, and at the end of 
the day, cells were treated with MG132 proteasome inhibitor. MG132 acts on the chymotrypsin-
like and caspase-like sites in the beta-subunit of the 20S proteasome to inhibit their function [80]. 
After this experiment, one would expect faint bands in the size of 70kDa in cells without MG132 
treatment, and much higher density bands in cells treated with proteasome inhibitor. Unfortunately, 
this was not the case (Fig. 5).  
Figure 5. Lack of Expression of Rearranged NS3 Protein. 293T cells were transfected overnight 
with rearranged Ub/NS3 and treated with MG132 inhibitor the next day. 20μg total cell lysate was 
analyzed via western blot for the expression of NS3 and beta-actin. Membrane was stained with 
Rabbit anti-NS3 antibody as well as Mouse anti-beta actin antibody.  
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Initial results indicate that, although there is high mRNA transcription in these 293T cells, 
there is no detectable protein translation occurring. However, upon western blot with ZIKV-
infected Vero cell lysates, the anti-NS3 antibodies in question showed no protein bands as well 
(data not shown). At this time, these results do not discredit the possibility that protein translation 
is occurring, but rather that this antibody is not detecting the NS3 protein properly. Other means 
of detection with alternate antibodies was necessary. As the encoded Ub/NS3 protein is innately 
ubiquitinated, one would expect an anti-ubiquitin western blot to show changes in NS3-specific 
band density under treatment with MG132. 293T cells were once again transfected with rearranged 
Ub/NS3 plasmid and subsequently treated with proteasome inhibitor the next day. A western blot 
was conducted using mouse anti-human ubiquitin antibodies. The bands of similar size to the 
Ub/NS3 protein produced by the anti-ubiquitin western blot were of similar density in both 
transfected as well as untransfected cells (data not shown). At this point, further samples of Anti-
ZIKV NS3 antibody were requested (Genetex). After repeated rounds of trial and error, it was 
found that the initial antibody delivered was generated from a short peptide within an undisclosed 
region in the NS3 sequence (Lot # GTX13309). A functioning antibody derived from 
immunization of a larger N-terminal region of the ZIKV NS3 protein (Lot # GTX133320) proved 
useful. 293T cells were transfected and treated with proteasome inhibitor in the same manner as 
done before and re-arranged Ub/NS3 protein expression was visualized (Fig. 6).  
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Figure 6. Rearranged Ub/NS3 Gene Sequence Transfection Results in Protein Expression. 
293T cells were transfected with rearranged Ub/NS3 plasmid overnight. The next day, media was 
changed and MG132 as added overnight. (A) 20μg total cell lysate was analyzed via western blot 
for the expression of NS3 and beta-actin. Membrane was stained with Rabbit anti-NS3 antibody 
as well as Mouse anti-beta actin antibody. (B) Total band density was quantified using ImageJ and 
analyzed using GraphPad (Prism). Statistical significance was calculated using a two-way 
ANOVA.  
As stated earlier, one would expect faint bands in the size of 70kDa in cells without MG132 
treatment, and much higher density bands in cells treated with proteasome inhibitor. Although one 
of the two transfected proteins display a faint band without MG132 treatment, the other band 
displays a relative cell density remnant of a non-degraded protein. When relative protein density 
was calculated with ImageJ, no statistical significance was found in transfected cells with or 
without MG132 addition (Fig. 6). These initial results do not prove the proteasomal destruction of 
the rearranged Ub/NS3 protein. It is possible, however, that inhibiting proteasomal function after 
12 hours of transfection does not allow 293T cells enough time to fully express and degrade a 
A B 
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70kDa protein. For that reason, 293T cells were transfected overnight with 10μg plasmid DNA 
delivered in PEI. In the morning, media was changed and 293T cells were allowed to stably express 
the transfected protein for 36 or 60 hours. After this period, cells were treated with 50μM MG132 
overnight. A western blot was then conducted to visualize the production of the rearranged Ub/NS3 
gene sequence (Fig. 7A). 
In both untransfected protein lanes, we do not see any production of the Ub/NS3 protein – 
this confirms that the antibody is not binding nonspecifically to any other proteins. Theoretically 
speaking, we should see faint NS3 bands in all experiments. Of the triplicate experiments shown 
in Fig. 7A, however, only one of the three shows faint protein bands in the transfected cell lanes 
without MG132 treatment. Furthermore, in a protein targeted for ubiquitination, treatment with 
proteasome inhibitor should result in bands with varying levels of ubiquitin laddering at 
incremental sizes above the band in question. Although that is not seen at a normal exposure level, 
upon overexposure, we do see smearing of the Ub/NS3 protein (Fig. 7c). Although we expect to 
see discrete bands varying by protein size of ubiquitin monomer, overexposure often leads to 
smudging in bands that leaves an often undiscernible result. Further experimental optimization is 
necessary in order to visualize discrete bands - although protein visualization only in the context 
of MG132 was a strong indicator.   
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Figure 7. Stable Expression of the Ub/NS3 Protein for 36 hours Shows Production and 
Degradation of Protein. 293T cells were transfected with rearranged Ub/NS3 plasmid overnight. 
The next day, media was changed cells were allowed to stably express plasmid for 36 hours. After 
this period, MG132 was added overnight. (A) 20μg total cell lysate was analyzed via western blot 
for the expression of NS3 and beta-actin. Membrane was stained with Rabbit anti-NS3 antibody 
as well as Mouse anti-beta actin antibody. (B) Total band density was quantified using ImageJ and 
analyzed using GraphPad (Prism). (C) Membranes from (A) were overexposed. Statistical 
significance was calculated using a two-way ANOVA. 
B 
C 
A 
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Pseudovirus Generation 
There are many viral structural proteins that have an innate ability to self-assemble into 
VLPs [81]. As VLPs structurally resemble the virus they were derived from, they still retain their 
high immunogenicity due to the peptide sequences present on their surface loops [82].  
Furthermore, the L1 proteins that comprise both HPV- and BPV-derived VLPs  can be engineered 
to present peptides on their surface [83-87]. These modified VLPs, called chimeric VLPs (CVLPs), 
can induce an immune response to any epitope located on their DE, FG, and HI loops and present 
a novel method for prophylaxis against any disease [82, 88, 89]. Moreover, pseudovirus has been 
found to induce three times more IFN-γ-producing CD8+ cells than injection with naked plasmid 
alone [65]. Because of this, VLPs can be used alone as a vaccine against the virus the VLP’s capsid 
protein was derived from, or can be used to encapsulate plasmid DNA [90] to ensure its delivery 
and expression into recipient cells. For this reason, we chose to package the rearranged Ub/NS3 
plasmid inside of a Bovine Papilloma Virus (BPV)-1-derived VLP. To do so, the L1 sequence 
derived from BPV-1 was inserted into a bacterial plasmid (dubbed “bacmid”). This L1 bacmid was 
then complexed with cellfectin and transfected into Sf9 insect cells. Media was changed in the 
morning, and cells were allowed to express the bacmid for 3-5 days. This bacmid encodes for a 
baculovirus, and further infects cells to generate the L1 protein. Upon visualization of enlarged 
and/or dead cells (7-10 days), the media containing the baculovirus was taken from the Sf9 cells, 
and further passaged in a suspension cell culture apparatus. After repeated passaging, cells were 
spun down and more baculovirus were added to the pellet for 2 hours, devoid of light. Cells were 
plated and allowed to grow for 3-4 days and were then spun down at 8,000 RPM. Pellet was lysed, 
and a western blot against the L1 protein was conducted (data not shown). VLPs were further 
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column purified and visualized under an electron microscope (Fig. 8). VLPs are a characteristic 
icosahedral shape and measure 45-55nm in diameter.  
 
Figure 8. Visualization of VLPs. After purification, VLPs were affixed to a copper grid coated 
with Poly-L-lysine. Once dried, the VLPs were imaged using an Electron Microscope.  
 
 Once VLPs were successfully obtained and visualized by EM microscopy, we then inserted 
the rearranged Ub/NS3 plasmid into the VLPs. To do so, BPV-VLPs were mixed with a disruption 
buffer in a 1:1 ratio and incubated for 1 hour at room temperature. The freshly made disruption 
buffer contains DTT, which is used to disrupt intermolecular disulfide bonds between cysteine 
residues of proteins [91], as well as EGTA, a Ca2+ chelator that will be useful going forward. After 
VLPs were successfully disrupted, plasmid was added at 835.2ng/μL in 1/10 volume of the 
VLP/disruption buffer mixture. Immediately afterwards, reassembly buffer was added. 
Reassembly buffer contains CaCl2, which allows EGTA to chelate the metal ion and facilitates the 
reformation of the L1 particles back into VLPs. Reassembly buffer was added in a 1:1 ratio 
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dropwise every 10 minutes at room temperature. Afterwards, the mixture was incubated at room 
temperature for 8 hours and stored at -20oC until visualization by EM (Fig. 9) 
 
Figure 9. Visualization of Pseudovirus. After purification, PVs were affixed to a copper grid 
coated with Poly-L-lysine. Once dried, the PVs were imaged using an Electron Microscope. 
 
  Discussion 
The goal of this study was to design a plasmid that will encode for a protein expressing a 
ubiquitin monomer fused to the open reading frame of a rearranged NS3 protein. As there are no 
conclusive ZIKV epitopes found in human MHC molecules, the conventional method of inserting 
SNPs in order to knock out gene function without affecting proper folding and subsequent 
immunogenicity could not have been conducted. Therefore, the gene sequence encoding for the 
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NS3 protein was split into three parts, reversed, and 30bp overhangs from each segment were 
placed in front of each splice site. This is expected to preserve all possible CTL epitopes as well 
as knock out function. By fusing the ORF of a ubiquitin monomer to this rearranged NS3 sequence, 
the protein will be targeted for polyubiquitination and destroyed [51]. To shed light onto how this 
mechanism acts, I will include a brief summary on ubiquitination. Ubiquitin covalently attaches to 
a K-48 residue on a target protein via its C-terminal glycine residue. A second ubiquitin then 
attaches onto the lysine residue from the first, and so on. This polyubiquitinated protein is taken 
to the proteasome, where it is further degraded into peptide fragments. In order to ensure 
generation of Ub/NS3-specific CTLs, we sought to ubiquitinate every plasmid-encoded protein. 
This was conducted by fusing the ORF of a mouse ubiquitin monomer upstream the NS3 gene 
region.  In constructs where an ORF encoding for a mouse ubiquitin monomer with a G76 residue 
is fused to the NS3 region, the resultant protein would be recognized by USP7 and deubiquitinated 
(Fig. 10). The USP7 protein is a ubiquitin-specific protease that cleaves ubiquitin from its target 
protein [92, 93].  
Figure 10. Proteasomal Targeting Schematic.  
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If this were the case, our plasmid-encoded protein of interest would not likely become 
ubiquitinated, would not be targeted to the proteasome for destruction, and would not be expected 
to induce an NS3-specific T cell repertoire. To circumvent this issue, others have shown that a 
mutation of G76 to A76 reduces the rate at which USP7 cleaves ubiquitin from its target protein by 
greater than 90% [94]. Knowing this, we modified the nucleotide sequence encoding for Glycine 
at position 76 to Alanine. By utilizing the GeneArt service by ThermoFisher, our sequence of 
interest was produced accurately and promptly.  
After successful ligation into our target vector (pVAX1), it was first necessary to prove the 
gene of interest could be transcribed in vitro. Our plasmid of interest was transfected into 293T 
cells using PEI overnight. The morning after, RNA was isolated, cDNA was synthesized, and qRT-
PCR was conducted. As seen in Fig. 3A, the fold induction in Ub/NS3 gene expression was 
150,562. Gene transcription was further confirmed by gel electrophoresis (Fig. 3B). This increase 
in fold change confirms the correct design of the rearranged Ub/NS3 plasmid. After successful 
transcription had been demonstrated, we next sought to observe plasmid translation. 
There comes an inherent difficulty with visualizing a protein that is ubiquitinated upon 
creation. To circumvent this problem and visualize a protein that is immediately targeted for 
destruction, we utilized MG132. After overnight transfection, 293T cells were cultured in 50μM 
MG132 overnight. In Fig. 6A, we see that there does appear to be production of the Ub/NS3 
protein. The bands in the transfected wells without MG132 have varying degrees of fluorescence, 
whereas the bands in the transfected wells with MG132 are consistently highly fluorescent. At this 
point, this experiment confirms protein creation, however it cannot conclusively report 
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proteasomal destruction of the Ub/NS3 protein. In order to observe a more conclusive result, 293T 
cells were re-transfected overnight. After media was changed the next morning, cells remained 
undisturbed for 36 hours. This amount of time is expected to allow sufficient expression and 
destruction of the target protein. After samples were run on a western blot, it was observed that, in 
all three cases, protein was visualized only in the presence of MG132 (Fig. 7A). This result 
suggests that the Ub/NS3 protein is not only produced, but is also targeted to the proteasome. 
Bands were overexposed to detect for laddering of polyubiquitinated proteins. Smearing, rather 
than laddering, was observed in one of three samples. Although this result is not ideal, further 
studies will be needed to confirm polyubiquitination – although protein visualization solely in the 
context of MG132 was a strong indicator.   
As the in vitro results suggest, this plasmid could possibly be used in an in vivo setting to 
induce the production of Ub/NS3-specific T cells. As this plasmid encodes for a peptide that is the 
most conserved across various strains of DENV, we predict it could offer protection against ZIKV 
as well.  
 
 
 
37 
 
                                                    CHAPTER FOUR 
IMMUNIZATION AND IN VIVO DETECTION OF NS3-SPECIFIC CD8+ T CELL        
REPERTOIRE 
                                                                   Introduction 
The ultimate goal of this project is to develop an effective vaccine that prevents ZIKV 
infection without inducing ADE. We reason that if the vaccine induces a strong ZIKV-specific 
CTL effector memory response, the T cells will respond immediately upon infection to control its 
proliferation. In humans, the ZIKV NS5 protein promotes proteasomal degradation of STAT2. As 
STAT2 is activated downstream the type I interferon receptor (IFNAR), degradation of the STAT2 
protein will lead to a decreased, if not completely abolished, IFN response [95, 96]. In contrast, 
the NS5 protein does not promote degradation of mouse STAT2, which may be the reason why 
immunocompetent mice are not natural hosts for the virus [95].  For this reason, many efforts have 
been focused on generating mouse models that show susceptibility to the virus. It has been found 
that mice with abnormalities in the type I IFN signaling pathway display enhanced susceptibility 
to flaviviruses such as DENV and YFV [97-99]. Multiple groups have evaluated the ability of 
these mice to support ZIKV replication and pathogenesis. Soon after, it was found that mice 
completely lacking the Ifnar1 gene develop severe disease and death [100-102]. Interestingly, it 
was found that lethality was age dependent. In ZIKV-infected A129 Ifnar1-/- mice, 
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100% of 3-week old mice died of ZIKV infection, whereas only 50% of 5-week old and 
none of the 11-week old mice died of infection [101]. Although this model provides a feasible 
method to evaluate the effects of ZIKV in vivo, the abolishment of a functional Ifnar1 gene 
provides an extreme means of testing. Ifnar1 knockout does not provide insight onto how mice 
may subtly react to the disease, as most mice with Ifnar-/- will immediately die during flavivirus 
infection.  
Instead of knocking out Ifnar1, Stat2 knockout mice have been shown to be a very useful 
model observing ADE. Unlike Ifnar1-/- mice, which show very extreme responses to ZIKV 
infection, Stat2-/- mice show less severe reaction. This allows us to monitor other ZIKV-induced 
symptoms, such as fever, weight loss, and partial limb paralysis based on previous flavivirus 
infection [103]. In a study conducted by the Bardina group, plasma from DENV-infected and 
WNV-infected individuals was administered intraperitoneally to Stat2-/- mice for two hours. It is 
believed that the difference in severity is due to partial knock out of the IFN pathway in Stat2-/- 
mice, as opposed to the complete knockout of the IFN pathway in the Ifnar1-/- mice.  Afterwards, 
5 x 103 PFU of ZIKV were administered intradermally. Mice who received plasma from DENV-
positive patients had a 20% survival rate after two weeks, and mice who received plasma from 
WNV-positive patients had a 60% survival rate. Mice that received control plasma had a 90% 
survival rate [103]. Furthermore, mice that received DENV-immune plasma developed a fever 3 
dpi, averaging a temperature of 38.3oC. Mice that received WNV-immune plasma developed a 
fever as well, although it was not as high as that of the DENV-positive plasma group. Mice that 
received control plasma had an insignificant increase in body temperature 3 dpi (37.6oC). This 
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model was the first to show a direct correlation between ADE and fever, and serves as a valuable 
tool in the development of a vaccine aimed at escaping ADE. Prior to the infection of Stat2-/- mice, 
it is necessary to show that the Ub/NS3 plasmid can induce an antigen-specific T cell response in 
a control mouse strain (BALB/C).  
Immunization of BALB/C Mice with Ub/NS3 Pseudovirus 
After PV was imaged via EM, pseudovirus number was calculated. To do so, Benzonase 
nuclease (Sigma) was added to 100μL Pseudovirus and incubated at 37oC for 60 minutes. This 
step is conducted to degrade any plasmids that may not have been incorporated into a VLP. The 
sample was then heated at 100oC to inactivate the nuclease. Proteinase K was added to disrupt 
interactions between the L1 proteins for 30 minutes at 56oC. Digested solution is then subjected to 
a phenol-chloroform extraction, after which point the L1 proteins should be denatured by the 
phenol and only internalized Ub/NS3/pVAX1 plasmid should remain. A nanodrop can then be 
used to calculate plasmid concentration, which then can be utilized in calculating pseudovirus 
number.   
𝐶𝑜𝑝𝑦 𝑁𝑢𝑚𝑏𝑒𝑟 =
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒 (𝑖𝑛 𝑙𝑖𝑡𝑒𝑟𝑠) ∗ 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑝𝑙𝑎𝑠𝑚𝑖𝑑 (𝑖𝑛
𝜇𝑔
𝜇𝐿)
𝑀𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟 𝑊𝑒𝑖𝑔ℎ𝑡 (𝑀𝑊)
∗ 6.02 ∗ 1023 
𝑀𝑊 𝑜𝑓 𝑎 𝑑𝑜𝑢𝑏𝑙𝑒 − 𝑠𝑡𝑟𝑎𝑛𝑑𝑒𝑑 𝐷𝑁𝐴 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒 = 𝑏𝑎𝑠𝑒𝑝𝑎𝑖𝑟𝑠 ∗ 660 𝐷𝑎𝑙𝑡𝑜𝑛𝑠  
𝑀𝑊 =  2181 ∗ 660 𝐷𝑎𝑙𝑡𝑜𝑛𝑠 = 1.43 ∗ 106 
𝐶𝑜𝑝𝑦 𝑁𝑢𝑚𝑏𝑒𝑟 =
(5𝑥10−5𝐿) ∗ (7.63 ∗ 10−2
𝜇𝑔
𝜇𝐿
)
1.43 ∗ 106
∗ 6.02 ∗ 1023 = 2.66 ∗ 1012𝑃𝑠𝑒𝑢𝑑𝑜𝑣𝑖𝑟𝑖𝑜𝑛𝑠 
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[𝑃𝑠𝑒𝑢𝑑𝑜𝑣𝑖𝑟𝑢𝑠] =
𝐶𝑜𝑝𝑦 𝑁𝑢𝑚𝑏𝑒𝑟
𝑇𝑜𝑡𝑎𝑙 𝑉𝑜𝑙𝑢𝑚𝑒
=
2.66 ∗ 1012
2 𝑚𝐿
= 1.33 ∗ 1012
𝑃𝑠𝑒𝑢𝑑𝑜𝑣𝑖𝑟𝑖𝑜𝑛𝑠
𝑚𝐿
𝑜𝑟 1.33 ∗ 109
𝑃𝑠𝑒𝑢𝑑𝑜𝑣𝑖𝑟𝑖𝑜𝑛𝑠
𝜇𝐿
   
50μL of pseudovirus were delivered in sterilized 1x phosphate buffered saline (PBS) to inject           
1 x 1010 VLPs in each mouse. To do so, one must first calculate how many VLPs/μL an injection 
must contain in order for 50μL of said injection to carry 1*1010 VLPs.  
(𝑥
𝑉𝐿𝑃𝑠
𝜇𝐿
) ∗ (50𝜇𝐿) = 1 ∗ 1010𝑉𝐿𝑃𝑠 
(𝑥
𝑉𝐿𝑃𝑠
𝜇𝐿
) =
1 ∗ 1010𝑉𝐿𝑃𝑠
50 𝜇𝐿
= 2 ∗ 108
𝑉𝐿𝑃𝑠
𝜇𝐿
  
In other words, a mouse injected with 50μL of pseudovirus at 2*108 VLPs/μL will receive 1*1010 
total VLPs. Next, one must calculate the amount of stock pseudovirus that must be used to obtain 
a final concentration of 2 * 108 VLPs/μL per mouse in 50μL of Pseudovirus diluted in 1X PBS: 
(1.33 ∗ 109
𝑉𝐿𝑃𝑠
𝜇𝐿
) ∗ (𝑥 𝜇𝐿) = (2 ∗ 108
𝑉𝐿𝑃𝑠
𝜇𝐿
) ∗ (50𝜇𝐿) 
𝑥 𝜇𝐿 =
((2 ∗ 108
𝑉𝐿𝑃𝑠
𝜇𝐿 ) ∗
(50𝜇𝐿))
1.33 ∗ 109
𝑉𝐿𝑃𝑠
𝜇𝐿
= 7.518𝜇𝐿  
For 1*1010 VLPs to be injected mouse quadriceps, 7.518μL of stock Pseudovirus at 1.33 * 109 
Pseudovirions/μL must be diluted into 50μL 1X PBS at a final concentration of 2 * 108 VLPs/μL 
A master mix was created with 500μL vaccine: 
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7.518𝜇𝐿 𝑃𝑠𝑒𝑢𝑑𝑜𝑣𝑖𝑟𝑢𝑠 𝑝𝑒𝑟 𝑚𝑜𝑢𝑠𝑒 ∗ 10 𝑚𝑖𝑐𝑒 =  75.18𝜇𝐿 𝑃𝑠𝑒𝑢𝑑𝑜𝑣𝑖𝑟𝑢𝑠 𝑖𝑛 500𝜇𝐿 𝑃𝐵𝑆 
Four mice were injected with 50μL of Pseudovirus and four mice were injected with 1X 
PBS. 14 dpi, mice were boosted with the same concentration of pseudovirus. After an additional 
14 days, a submandibular (cheek) bleed was conducted. Mice were then euthanized in a CO2 
chamber followed by cervical dislocation. Blood was allowed to clot for two hours, after which 
samples were centrifuged at 13,000 rpm for 20 minutes. Serum was extracted from the top layer 
of the tube. Mouse spleen was removed and washed in 1X PBS. After washing, the spleen was 
placed above a 70μm filter and passed through with repeated force. The filter was washed with 
10mL RPMI-1640 (Hyclone) and eluate was collected in a 50mL conical tube.  
Detection of Antigen-Specific T cells 
T-cell receptors (TCRs) detect antigen in the context of peptide bound to MHC molecules 
on the surface of antigen presenting cells. CD4+ T cells bind to MHC Class II molecules, whereas 
CD8+ T cells bind to MHC Class I molecules. This TCR-MHC interaction determines 
differentiation, proliferation, and the ultimate fate of a T cell [104]. From its conception in 1968 
to 1996, the chromium release assay was the canonical method for the detection of antigen specific 
T cells [105-107]. In this method, target cells are incubated with peptide and radiolabeled with 
Chromium 51. Radiolabeled target cells are pulsed with a serial dilution of peptide-specific CD8+ 
T cells. If the T cells showed specificity towards that specific peptide sequence, they would then 
lyse the target cells. The target cells would release 51Cr, which could then be quantitated with a 
scintillation counter [108].  
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 Although a perfectly functional assay, most research has moved away from this method. 
Researchers have since worked to create fluorescently labeled MHC molecules conjugated to a 
peptide that could detect antigen-specific T cells. TCRs bind to monomeric MHC’s with very low 
binding affinities (Kd 200,000 higher than that of a typical antibody-antigen interaction) [109]. To 
circumvent this problem, researchers have constructed soluble MHC Class I peptide-bearing 
molecules linked together in the form of a tetramer [110, 111]. These peptide-labeled tetramers 
are able to bind to specific TCRs with a much higher affinity than monomeric MHC molecules. 
These molecules make it possible for quantification of antigen-specific T cells without the prior 
need for in vitro expansion. While MHC tetramer technology has been well characterized in the 
context of human antigen-specific T cells, detection of mouse antigen-specific T cells uses a 
similar technology.  
 Whereas MHC tetramers link MHC molecules via the four biotin-binding sites on 
streptavidin, MHC dextramers carry a much more variable number. MHC dextramers, instead, 
consist of a dextran polymer backbone attached to MHC-peptide complexes and fluorophores to 
ultimately carry larger numbers of both. This allows for brighter staining over tetramers. 
Furthermore, MHC dextramers often outperform conventional tetramers in situations where TCR-
MHC affinity is naturally low [112]. In order to best visualize the Ub/NS3-specific T cells, we 
chose to use H2-K(d) restricted MHC dextramers on splenocytes harvested from BALB/C mice as 
BALB/C mice display a K(d)-restricted HLA type.  
 Now that we have obtained a simple method of Ub/NS3-specific T cell detection, we must 
decide which peptide to load onto the MHC molecules. Unfortunately, no studies have found 
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definitive antigenic CTL epitopes in ZIKV. Some studies have, however, made use of 
computational prediction analysis to identify possible CTL epitopes [113]. A software called 
NetMHCpan3.4, often used in predicting well performing MHC-binding peptide sequences, found 
a total of 61 CTL epitopes across the three structural and seven non-structural protein sequences 
that make up the ZIKV viral genome. Although 61 epitopes seem to be a generous number of 
peptide sequences to have to choose from when loading a peptide onto an MHC molecule, not all 
of these peptides are conserved across multiple strains. In a project whose goal is to provide 
maximal coverage against the NS3 protein, we sought to find a ZIKV NS3 epitope that would be 
conserved across all (or most) strains of ZIKV. Unfortunately, of the 61 epitopes that were 
predicted, only 9 of them exhibited promiscuity amongst different strains of ZIKV – none of which 
were generated from the NS3 protein [113]. In addition to computational analysis, large efforts 
have been made to identify CTL epitopes in ZIKV based on homology to other known flaviviruses 
[114]. As the ZIKV and DENV viral genomes are highly similar, we sought to identify the DENV 
NS3 CTL epitopes with the highest population coverage. The nonamer peptide with the most cross-
species coverage in all four of the DENV strains was GYISTRVEM [115]. This epitope is fully 
conserved in both the wild type ZIKV NS3 and the rearranged Ub/NS3 amino acid sequence. 
Therefore, this peptide was chosen to be detected via MHC dextramer analysis. Successful 
detection of T cells specific to this peptide should, in theory, signify production of a T cell 
repertoire capable of providing sufficient immunity against ZIKV infection.  
 After conducting flow cytometry, one would expect to see populations which are 
CD8+/MHC-Dextramer+ in mice vaccinated with the rearranged Ub/NS3 pseudovirus. This was 
not the case (Fig. 11). Each flow cytometry graph represents one mouse. MHC-Dextramer 
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populations were viewed on the X-axis, whereas CD8+ populations were viewed on the Y axis.  
As seen in each of the PBS treated mice, the percentage of splenocytes that were double positive 
ranged from 1.36-1.81% of splenocytes. In each of the vaccine treated mice, splenocytes double 
positive for CD8/MHC dextramer fell within that same range – possibly indicating that there was 
no upregulation of Ub/NS3-specific CD8+ T cells.  
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MHC-Dextramer 
Vaccine Treated Mice 
Figure 11. Detection of Antigen-specific T cells by Flow Cytometry. Mouse splenocytes were 
harvested and stained with PE-conjugated MHC dextramer as well as FITC-conjugated anti-CD8a 
antibody. Percentages of cells positive for each marker is located in the number adjacent to each 
population. Upper left – CD8 positive, MHC dextramer negative. Bottom left, CD8/MHC dextramer 
double negative. Bottom Right – CD8 negative, MHC dextramer positive. Top Right – CD8/MHC 
dextramer double positive.  
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There are three possible reasons why upregulation of Ub/NS3-specific T cells was not 
observed: (1) Although the Ub/NS3 plasmid showed expression in a 293T transfection system, 
there was no transcription/translation of the rearranged plasmid in a mouse model. (2) Our methods 
of detecting what should be a 0.5-1% increase in antigen-specific T cell number are not sensitive 
enough. (3) The route of vaccination used did not suitably induce immunogenicity and deliver 
plasmid sufficiently. Due to the nature of this construct, the resultant translation product led to the 
production of an overly misfolded protein which was very difficult to detect. After all theories 
were explored, discrepancies in VLP formation were found. Upon re-inspection of VLPs via EM, 
no VLP’s could be visualized. In between primary visualization of pseudovirus and infection, 
VLP’s were kept in the -20oC freezer, where they are assumed to be the most stable. It was found 
that although VLP’s are stable at both -20oC and 4oC, a study has shown that VLPs derived from 
HIV-1 Pr55gag can withstand 2 freeze-thaw cycles, after which >50% lost their uniform spherical 
shape [116]. As all VLPs used in the creation of pseudovirus were saved at -20oC were presumed 
to be denatured as well, a new method of delivery of the Ub/NS3 plasmid was needed.  
Immunization of BALB/C Mice with Naked DNA Supplemented with Adjuvant 
The first study to demonstrate stable antigen expression due to a DNA vaccine delivered 
in vivo was through the intramuscular route [117]. The injection of naked DNA into skeletal muscle 
was meant to be used as a negative control designed to assess the ability of cationic lipids (such as 
in vivoJet PEI) to mediate plasmid expression in vivo. Surprisingly, naked DNA expressed reporter 
genes such as luciferase and beta-galactosidase just as well as lipid-complexed DNA [68]. Since 
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then, many studies have reported the safety as well as efficacy of naked DNA in inducing an 
immune response [118-121]. In addition, naked DNA injected i.m. shows very little transfection 
at distant sites following delivery and can be re-administered multiple times without inducing an 
antibody response against the plasmid itself [122], making it an attractive method for plasmid 
delivery. Along with injection of naked vaccine, we sought to use an adjuvant in order to increase 
the immunogenicity of the plasmid. 
As alluded to earlier, immunogenicity of plasmid DNA can be manipulated via the 
insertion of CpG islands into the plasmid sequence, as well as co-delivery of cytokines. Multiple 
approaches were made in order to make the DNA plasmid as immunogenic as possible. By 
rearranging the NS3 gene sequence, as well as introducing a ubiquitin monomer at its 5’ end, 
twelve unmethylated CpG sites were introduced. These CpG motifs are recognized by TLR3 and 
TLR9, and induce the expression of pro-inflammatory cytokines as well as type I IFN [123-125]. 
Furthermore, we sought to a supplement a chemical adjuvant alongside naked plasmid injection. 
Gardiquimod VacciGrade is a TLR7 agonist (Invivogen). TLR7 recognizes single-stranded RNA, 
which further stimulates recruitment and activation of macrophages and dendritic cells.  These 
cells not only present antigen to CD8+ T cells, but also release cytokines optimal for Th1 cell-
mediated immunity [126, 127]. The use of Gardiquimod VacciGrade is to facilitate the recruitment 
of macrophages and dendritic cells to the site of injection, where the plasmid which initially 
entered somatic cells can be engulfed by APCs for eventual MHC presentation and CTL activation.  
In a second set of experiments, BALB/C mice were injected i.m. with 10μg naked Ub/NS3 
DNA alongside 20μg Gardiquimod VacciGrade diluted to a volume of 50μL in 1X PBS. A positive 
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control group of mice receiving WT NS3 plasmid was also used. This group, which encodes for 
the GYISTRVEM peptide, should not be subjected to any of the intracellular mechanisms possibly 
hindering expression of the rearranged Ub/NS3 plasmid. This peptide sequence is a confirmed 
CTL epitope in BALB/C mice in the context of DENV-4, and is also present in the Ub/NS3 gene 
sequence. Therefore, we anticipated detection of NS3-specific CTLs in mice immunized with this 
plasmid. Rather than receiving a booster injection at 2 weeks, mice were boosted at 3 weeks and 
spleens were harvested one week later in order to allow for further generation of memory T cells 
[128]. FACS analysis was subsequently conducted (Fig. 12). In mice treated with 1X PBS alone, 
CD8/MHC Dextramer+/+ T cells varied from 1.76% to 3.49% of the total cell population. These 
numbers are abnormally high as antigen-specific T cell numbers should be less than 0.5% of a total 
population.  In mice treated with the rearranged Ub/NS3 plasmid complemented with Gardiquimod 
VacciGrade, CD8/MHC Dextramer+/+ T cells varied from 1.43% to 2.62% of total cell population. 
This T-cell subset percentage fell within the same range of double positive cells induced in 
response to PBS injection – indicating no statistical difference in Ub/NS3-specific T cell induction. 
Furthermore, mice injected with WT NS3 plasmid generated double positive T cell responses 
varying from 1.37% to 1.68% of the total cell population. This result is unexpected, as wild type 
NS3 protein is likely transfected in vivo and presented onto MHC class I molecules - where 
antigen-specific T cell generation is expected to be abundant. This led us to believe one of two 
things: (1) There are not enough Ub/NS3-specific T cells present to view a very small increase in 
T cell production. (2) The MHC Dextramer in question may not be binding specifically to antigen-
specific T cells. Upon further questioning of the integrity of the product, it was revealed that 
Immudex could provide no means of positive control to validate the function of this dextramer in 
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its ability to bind to a TCR of interest. For this reason, we then sought to find a new method to 
detect for antigen-specific T cells, as well as magnify small changes in T cell formation.  
 
 
 
 
 
 
 
 
 
 
 
 
50 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PBS Treated Mice Vaccine Treated Mice WT NS3 Treated Mice 
C
D
8
 
MHC-Dextramer 
Figure 12. Repeated Flow Cytometry Analysis. Mouse splenocytes were harvested and stained 
as described before. Percentages of cells positive for each marker is located in the number 
adjacent to each population. 
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7-Aminoactinomycin D / 5(6)-Carboxyfluorescin Diacetate Succinimidyl Ester based 
Method of Detection for Antigen-Specific T cells 
7-Aminoactinomycin D/5(6)-Carboxyfluorescin Diacetate Succinimidyl Ester (7-
AAD/CFSE) dye employs CFSE to label target cells in a mixed cell population and 7-AAD to 
label dead cells. In comparison to the more dated 51Cr release assay, this method of antigen-specific 
T cell detection does not employ the use of radiolabeled compounds. In order to use this kit, 
antigen-specific T cells must be expanded ex vivo. To do so, splenocytes were harvested from 
BALB/C mice, washed with 1X PBS, and passed through a 70μM as previously described 
Splenocytes were spun down at 1200 rpm for 5 minutes and subsequently resuspended in 
Ack Lysis Buffer (150mM NH4Cl, 10mM KHCO3, 100μM Na2EDTA) in order to lyse any 
erythrocytes present. The remaining splenocytes were then seeded at a concentration of 1x106 
cells/mL into two 96 well plates and cultured with 5μg/mL GYISTRVEM and 10% T-stim without 
Concanavilin A. T-stim is an IL-2 culture supplement that is used in the proliferation of antigen-
specific mouse lymphoid T-cells [129]. Concanavilin A has been found to induce the activation of 
non-specific T cells, therefore it was omitted. In this technique, any peptide-specific T cells will 
be further stimulated, where they can survive and proliferate. Any CTLs not specific to the peptide 
will eventually apoptose. This method is meant to amplify the number of antigen-specific T cells 
for enhanced detection. T-cell stimulation occurred for 7 days. After this period, Ficoll/Hypaque 
separation was used to discern between live and dead cells by centrifugation at 1500 rpm for 15 
minutes without brakes. In this method of separation, dead cells will pellet at the bottom of the 
tube, whereas live cells will be located at the Ficoll/Cell culture media interface. Live cells were 
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collected, washed twice, and counted. Splenocytes were then co-cultured with target P815 cells 
loaded with GYISTRVEM peptide labeled with CFSE for four hours. Cell mixture was then 
labeled with 7-AAD to visualize dead cells and flow cytometry was conducted.  
Effector and target cells were co-cultured in a 1:1 ratio of target: effector cells (Fig. 13). In 
the target cells treated with a 1:1 ratio of effector cells, mice injected with PBS displayed 18.6% 
total cell death (as evidenced by CFSE- populations). In mice treated with vaccine, target cells 
cultured in a 1:1 ratio with effector cells exhibited 51.7% cell death. Lastly, in mice treated with 
wild type NS3 plasmid, target cells cultured in a 1:1 ratio of effector cells displayed 43.5% 
cytotoxicity – 24.9% greater cytotoxicity than PBS treated mice. These results possibly indicated 
the upregulation of Ub/NS3-specific T cells in the context of vaccine. The wild type NS3 plasmid 
should be processed and displayed in a manner similar to that of the rearranged Ub/NS3 plasmid. 
Therefore, it is expected that for mice treated with the wild type plasmid to induce an upregulation 
of NS3-specific T cells.   
To further support these findings, in vitro 
cell observation under a standard light microscope 
was able to shed light on possible differences in 
cytotoxicity between PBS, Ub/NS3, and WT NS3 
treated splenocytes (Fig. 14).  
 
Figure 13. DNA Vaccine as Well as Wild Type NS3 Plasmid Induce Antigen-Specific CTL 
Upregulation. Target cells labeled with peptide were stained with 7-AAD/CFSE and were subsequently 
co-cultured at 1:1 effector: target ratios for 4 hours. Flow cytometry and data analysis was conducted by 
Patricia Simms in the flow center.  
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 Although visualization of cell-cell interaction under a light microscope by no means allows 
us to come to a definitive conclusion, these data, along with the previous, do indicate that 
splenocytes are binding to P815 target cells differently based on vaccine treatment. This is 
evidenced by the differences in size of cell aggregates in splenocytes of PBS-treated mice versus 
those injected with either wild type NS3 or Ub/NS3. Further investigation as to the biological 
significance of this change must be further explored by challenge with ZIKV.  
Discussion 
The goal of this study was to observe a CD8+ T cell population in wild type BALB/C mice. 
This population would indicate that the plasmid of interest was indeed transcribed/translated in 
vivo, as well as encoded for an antigen that would be further destroyed by the proteasome and 
presented via the context of the MHC Class I molecule to CD8+ T cells. Once the presence of this 
T cell subset is confirmed, further studies would be conducted to determine if the vaccine can 
provide protection against ZIKV challenge. In order to efficiently deliver the plasmid DNA to host 
cells, we first sought to package them in VLPs. VLPs present a novel way to induce 
PBS    WT NS3   Ub/NS3 
Figure 14. Visual Differences in Splenocyte Binding. Target cells labeled with peptide were 
stained with CFSE and were subsequently co-cultured at 1:1, 3:1, and 10:1 effector: target ratios for 4 
hours. Cells were visualized under a light microscope. 
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immunogenicity of plasmid DNA in both an intramuscular as well as mucosal route of entry [65, 
129].  Pseudovirus was first administered at 1x1010 pseudovirions/mouse via i.m. injection. After 
two weeks, mice were boosted with the same dosage of pseudovirions. After two more weeks, 
blood was collected via submandibular bleed and mouse spleen was harvested. We first sought to 
detect an antigen-specific T cell population using an MHC dextramer. The results of our first 
experiment suggested that injection of pseudovirus carrying the rearranged Ub/NS3 plasmid bore 
no effect on the generation of antigen-specific T cells (Fig. 11). This conclusion was drawn on the 
basis that all four mice from each treatment group had non-statistically significant differences in 
the percentage of cells that were CD8+/MHC Dextramer+. After further imaging of the VLPs used 
in this vaccination, it was found that too many freeze/thaw cycles had been conducted – which led 
to degradation of the VLPs and greatly reduced immunogenicity (data not shown). Due to this 
result, an alternate method of vaccination was necessary.  
 The immunogenicity, as well as the safety, of naked DNA injection has been shown 
repeatedly [130, 131]. We sought to recapitulate this success by incorporating unmethylated CpG 
islands in our plasmid sequence, as well as introducing an adjuvant alongside our naked plasmid. 
By rearranging the NS3 gene sequence, as well as introducing an ubiquitin monomer at the 5’ end 
of the rearranged NS3 sequence, twelve CpG sites were introduced. To further increase 
immunogenicity of our vaccine, we incorporated an adjuvant alongside the naked plasmid DNA. 
Gardiquimod VacciGrade is a TLR7 agonist that acts to further stimulate recruitment and 
activation of macrophages and dendritic cells. As a further revision to the initial immunization 
experiment, mice were boosted at 3 weeks post immunization and spleens were harvested one 
week later. In addition to vaccination with naked Ub/NS3 plasmid as well as 1X PBS, mice were 
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immunized with a wild type NS3 mammalian expression plasmid (Sino Biological). Whereas it is 
unsure to what immune response mice immunized with Ub/NS3 will elicit, mice immunized with 
wild type NS3 serve as a positive control. The mice receiving this plasmid will most certainly 
express NS3-derived peptide on their MHC class I molecules, and should be detected by MHC 
dextramer analysis. In addition, due to the lack of ubiquitination on the wild type NS3 plasmid, 
this vaccine treatment should elicit both a CD8+ specific response as well as a humoral response. 
When using MHC dextramer to again detect for the generation of antigen-specific T cells, no 
statistically significant difference was found. Surprisingly, mice treated with the wild type NS3 
mammalian expression plasmid exhibited no higher MHC dextramer binding over the PBS or 
Ub/NS3 treated mice. As these mice should have no theoretical difficulties in generating an anti-
NS3 CTL response, we sought to fine-tune our methods of CTL detection.  
 There are no known CTL epitopes presented in BALB/C mice, but multiple efforts have 
been made to predict them [113, 115]. In addition, many have sought to identify potential CTL 
epitopes in ZIKV based on homology to other known flaviviruses, such as DENV and WNV [114]. 
With knowledge that ZIKV and DENV exhibit high sequence similarity, we sought to detect the 
DENV NS3 CTL epitope with the highest cross-species coverage – GYISTRVEM. Although the 
proteasome can degrade antigenic protein in a manner in which specific epitopes are presented 
more than others, it is possible that our epitope of choice is only being used to generate a very 
small antigen-specific T cell subset. If this were the case, there would be very few Ub/NS3-specific 
CTLs. This would lead to a very nominal difference in a double-positive population during flow 
cytometry analysis. To correct for this, mouse splenocytes were harvested, subjected to erythrocyte 
lysis, and cultured in the presence of peptide and 10% T-stim for 6 days. With this treatment, all 
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peptide-specific T cells will be stimulated and proliferate, whereas all non-specific T cells will 
apoptose. Additionally, rather than detect these antigen-specific cells with the MHC dextramer, a 
7-AAD/CFSE assay was conducted. In this assay, target cells are labeled with peptide and stain 
with CFSE – a general cell viability dye. Cells are then further co-cultured with titrating amounts 
of the stimulated T cell population. After 4 hours, co-cultured cells are stained with 7-AAD. 
CFSE/7-AAD+/+ cells were observed via flow cytometry. Although non-specific target cell death 
occurred, the wild type and Ub/NS3 treated mice showed 33.1% and 24.9% more cytotoxicity, 
respectively. Further visualization of differences in cells derived from PBS-treated mice against 
those derived from wild type NS3 and Ub/NS3 treated mice showed enhanced CTL-P815 binding 
(Fig. 14). While these differences need to be replicated in order to detect for statistical significance, 
biological significance can only be proven with further challenge of Ub/NS3 immunized mice with 
ZIKV. Further studies detecting the production of antibodies must be repeated as an NS3 ELISA 
showed no conclusive results (data not shown). Furthermore, if the plasmid shows ability to protect 
from ZIKV infection, studies treating Stat2-/- mice with ZIKV and DENV post-immunization will 
show if vaccination with Ub/NS3 will inhibit ADE.   
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CHAPTER FIVE 
CONCLUSIONS 
Previous in vivo studies regarding the use of DNA vaccines have used an antigen-encoding 
plasmid to protect viruses including but not limited to: Hepatitis B, Hepatitis C, HIV, HPV, 
Malaria, Renal Cancer, Melanoma, and more [45]. There are several ZIKV vaccine candidates 
currently in clinical trials. These vaccine candidates have been designed to induce both 
neutralizing antibodies as well as ZIKV-specific CTLs [132]. Due to the potential ability of ZIKV 
antibodies to induce ADE, as well as the difficulty in attaining high levels of ZIKV-neutralizing 
antibodies, alternative vaccine strategies must be implemented.  To our knowledge, this is the only 
ZIKV vaccine approach which aims to create an exclusively CD8+ response to provide immunity 
against infection. Our data demonstrate that a plasmid encoding for a ubiquitin-tagged NS3 protein 
can be transcribed with high expression rates, and translated such that it will be immediately 
targeted to the proteasome. The use for such a protein is its ability for the resultant peptides to be 
loaded onto the MHC class I molecules, bind to the TCR, and induce the proliferation of an anti- 
Ub/NS3 T cells. In vivo assays demonstrate the functionality of this DNA vaccine to induce the 
upregulation of an anti-NS3 CTL population. Further studies investigating the use of this plasmid 
in conferring protection against Zika virus will confirm success in this plasmid to be used as a 
clinical candidate. 
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